Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01

BACKGROUND: VRC01 is a human IgG1 broadly neutralizing antibody (bnAb) that binds to the HIV-1 envelope glycoprotein. It is being evaluated in two ongoing efficacy trials, the first assessment of a passively-administered bnAb for HIV-1 prevention. HVTN 104 was a Phase 1 trial of VRC01. SETTING: We m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Acquir Immune Defic Syndr
Hlavní autoři: Huang, Yunda, Zhang, Yuanyuan, Bailer, Robert, Grunenberg, Nicole, Carpp, Lindsay N., Seaton, Kelly, Mayer, Kenneth H., Ledgerwood, Julie, Corey, Lawrence, Mascola, John, Montefiori, David, Gilbert, Peter B.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594341/
https://ncbi.nlm.nih.gov/pubmed/31855881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002272
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky